Pacific Biosciences of California, Inc. (PACB) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Pacific Biosciences of California, Inc. (PACB), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Pacific Biosciences of California, Inc., analysts forecast revenue rising from $158.43M in 2025 to $273.40M in 2030; the average estimate for 2030 earnings per share is −$0.19; with published estimates ranging from −$0.20 to −$0.18; 5 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Pacific Biosciences of California, Inc. (PACB) forecast — frequently asked questions
What is the analyst price target for Pacific Biosciences of California, Inc.?
Analysts covering Pacific Biosciences of California, Inc. (PACB) have a consensus price target of $1.93, 6.0% above the current price of $1.82. Published targets range from $1.35 to $2.50. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Pacific Biosciences of California, Inc.'s earnings?
The average analyst estimate for Pacific Biosciences of California, Inc. (PACB) earnings per share in 2030 is -0.19, with individual estimates between -0.20 and -0.18.
How much revenue is Pacific Biosciences of California, Inc. expected to make?
Analysts forecast Pacific Biosciences of California, Inc. (PACB) revenue of $273.40M in 2030, based on 2 published estimates.
How many analysts cover PACB?
5 analysts contribute estimates for Pacific Biosciences of California, Inc. (PACB). Thin coverage makes an average less reliable.
Analyst forecasts for other Medical - Devices stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.